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Background: Treatment of HCV with direct-acting antivirals has enabled the discussion of HCV eradication
worldwide. Envisioning this aim requires implementation of mass screening in resource-limited areas, usually
constrained by testing costs.
Methods: We validated a low-cost, rapid diagnosis test (RDT) for HCV in three different continents in 141
individuals.
Results: The HCV RDT showed 100% specificity and sensitivity across different samples regardless of genotype
or viral load (in samples with such information, 90%).
Conclusions: The HCV test validated in this study can allow for HCV screening in areas of need when properly
used.
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Introduction
HCV is responsible for 400 000 deaths a year, with a large pro-
portion of these deaths occurring in low- and middle-income
countries.1 While new curative therapies for HCV are now
becoming affordable in more regions of the world, many
infected persons remain untreated due to limited access to cen-
tralized laboratory testing and cost restrictions for mass testing
in areas of need.2 We aimed to perform an external validation
of a rapid diagnostic test (RDT) for HCV using study populations
from three different regions of the world.
Material and methods
The studied RDT measures anti-HCV antibodies in serum (anti-HCV
cassette, PRECHEK Bio. Inc., Korea) and gives a qualitative result
(positive/negative) within minutes based on double antigen sand-
wich immunoassay. Monoclonal antibodies against HCV antigens
are conjugated with colloidal gold, deposited in the pad and immo-
bilized on the test line in the nitrocellulose membrane. As serum is
added it rehydrates the gold–antibody conjugate. In positive sam-
ples the antigen–antibody–gold complex will migrate towards the
test window until the test zone (T), where it is captured by immobi-
lized antibodies, forming a visible line, which indicates a positive
reaction. Tests were performed according to the manufacturer’s
instructions, using serum obtained from hospitals in The
Netherlands, Argentina and Ethiopia. The performance of the RDT
was assessed by receiver operating characteristic (ROC) curve ana-
lysis, using the local diagnostic standard as the reference test
(Argentina: ARCHITECT anti-HCV Reagent kit from Abbott, Germany;
The Netherlands: LIAISON XL system from Diasorin, Italy; Ethiopia:
HCV Rapid Test from Assure Tech, China). Statistical analyses were
performed using STATA version 15.1 (StataCorp LP, College Station,
TX, USA). Patients coinfected with HIV were not included.
Results and discussion
Serum samples from 141 patients were tested using the anti-
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known HCV-negative samples were tested. Ninety samples were
tested in The Netherlands, 41 in Argentina and 10 in Ethiopia.
The median age of patients was 46 y (IQR 39–54) and 65%
were male. HCV genotype was available in 96 patients, with 61
samples belonging to genotype 1, 21 to genotype 2, and 7 each
to genotypes 3 and 4 (Table 1). The median HCV RNA level
(available in 67 patients) was 800 000 IU/ml (IQR 80 000–4 200
000). The HCV RDT had a sensitivity and specificity of 100% (CI
94.9 to 100 and 92.9 to 100, respectively) in all genotypes and
all RNA levels, including <15 copies, which was the lower level
of detection for quantitative assays. As the WHO aims to
achieve 90% diagnosis of HCV by 2030, it is critical to validate
rapid tests in resource-rich as well as resource-limited settings.3
In this study, we demonstrate that the PRECHEK Bio. Inc. anti-
HCV cassette RDT is highly sensitive and specific for the diagno-
sis of HCV. By testing the RDT in three different countries from
three separate continents, as well as testing four different HCV
genotypes, we are able to establish that the test is likely to be
reliable in a variety of populations. While several point-of-care
RDTs are commercially available, many rely on expensive instru-
ments, making them ill-suited for resource-limited settings.4 In
contrast, the RDT tested in this study is a chromatographic
immunoassay that does not require extra instrumentation,
making it both affordable and appropriate for rural sites.
Importantly, test results are available in <10 min. Moreover, the
calculated cost of the test is approximately 1–2% that of
approved WHO ones (depending on order volume and location),
making it realistically affordable for limited settings. Some of
the limitations of our study include a relatively small sample
size, as well as a lack of assessment of active viral replication
(HCV RNA) in all samples. However, we believe the ease of use,
rapid result yield and very low cost of this RDT could increase
the proportion of patients aware of their HCV status in all geo-
graphical regions, thus enabling treatment when possible.
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Table 1. Patient characteristics by country
The Netherlands Argentina Ethiopia
Number 90 41 10
Median age, y1 48 (39–55) 46 (40–50) 48 (39–55)








1Medians are displayed with IQR (Q1–Q3).
2Genotype data was unavailable in Ethiopia.
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